NCT/Study#
NCT03147742 /
INCB18424-MA-GD-301
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
DISEASE GROUP:
Transplant
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
